Abstract: Disclosed are a low-cost high-efficiency drip irrigation system for a cotton field and a use method thereof. The drip irrigation system for a cotton field includes a filtering device and a water supply device; wherein the filtering device adopts different types of single filtering devices or combined filtering devices according to different water source types; the water supply device includes multiple stages of main pipes, submain pipes and laterals; the laterals (a drip irrigation tape with labyrinth on one side or a drip irrigation tape inlaid with emitters inside) are laid on the surface of the ground and located below a mulch film. The drip irrigation system adopts the design of large flow (1.5-3.4 L/h), slightly larger pipe diameter (>75 mm), low water pressure (operating pressure of drip irrigation tape being 0.03-0.07 MPa) and suitable drip irrigation uniformity (80%-90%).

Abstract: The present invention belongs to the field of medicinal chemistry and relates to a class of substituted tricyclic compounds as PRMT5 inhibitors and the use thereof. Specifically, the present invention provides a compound represented by formula (A) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, a preparation method therefor, a pharmaceutical composition containing the compounds, and the use of the compounds or the composition for treating a disease mediated by PRMT5. The compounds of the present invention show significant inhibitory activity on PRMT5.

Abstract: Electrolytes and electrolyte additives for energy storage devices comprising cyanate based compounds are disclosed. The energy storage device comprises a first electrode and a second electrode, wherein at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, an electrolyte comprising at least two electrolyte co-solvents, wherein at least one electrolyte co-solvent comprises a cyanate based compound.

Abstract: Provided are an anti-CD47/anti-PD-L1 antibody, a pharmaceutical composition of the anti-CD47/anti-PD-L1 antibody, and applications thereof. The anti-CD47/anti-PD-L1 antibody provides antitumor activity, is free of significant red blood cell toxicity, and is applicable in preparing an antitumor medicament.

Abstract: The present invention falls within the field of medical chemistry and relates to a class of compounds as SHP2 inhibitors and the use thereof. Specifically, the present invention provides a compound represented by formula (I), or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, a preparation method therefor, a pharmaceutical composition comprising the compounds, and the use of the compounds or the composition for treating a disease mediated by SHP2.

Abstract: Provided is an anti-B7-H3 antibody or antigen-binding fragment thereof, a pharmaceutical composition containing the anti-B7-H3 antibody or antigen-binding fragment thereof, and an application thereof. The anti-B7-H3 antibody or antigen-binding fragment thereof of the present invention has high affinity and stability, and can be used for preparing antitumor drugs.

Abstract: Provided are an anti-Claudin18.2 antibody or an antigen binding fragment thereof, a pharmaceutical composition comprising an anti-Claudin18.2 antibody or an antigen binding fragment thereof, and uses thereof. The antibody and Claudin18.2 have significant binding activity and affinity, have efficient in-vitro ADCC cytotoxic activity against a tumor cell, and can be applied in the preparation of an antineoplastic drug.

Abstract: The present disclosure relates to the technical field of antibody drugs, and in particular, to an anti-CD47 antibody or an antigen-binding fragment thereof, a pharmaceutical composition comprising the anti-CD47 antibody or the antigen-binding fragment thereof, and applications thereof. The anti-CD47 antibody or the antigen-binding fragment thereof has significant antitumor activity and high affinity with human CD47 protein, can eliminate the capability of SIRPa to bind to CD47 on a surface of a cell, and does not have significant hemoagglutination activity and thus can be applied to the preparation of an anti-tumor drug.

Abstract: Monobactam compounds and a use therefor. Specifically provided are chemical compounds represented by formula (I) or isomers, pharmaceutically acceptable salts, solvates, crystals, or prodrugs thereof, preparation methods therefor, pharmaceutical compositions containing said compounds, and a use of said compounds or compositions in treating bacterial infection. The present compounds feature excellent antibacterial activity, and have great hopes of becoming a therapeutic agent for bacterial infection.

Abstract: The present application relates to a compound as a TGF-? R1 inhibitor and application thereof. Specifically, provided are a compound of formula I, or an isomer, pharmaceutically acceptable salt, solvent, crystal, or prodrug thereof, preparation methods therefor, and pharmaceutical compositions comprising these compounds, and applications of these compounds or compositions in treating and/or preventing TGF-? R1-related diseases, such as cancer, tissue proliferation diseases, fibrosis, and inflammatory diseases. The compound represents a significant inhibitory activity for TGF-? R1 kinase, and is promising as a treatment agent for TGF-? R1-related diseases.

Abstract: Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases.

Abstract: Provided are a chemical compound of an isocitrate dehydrogenase inhibitor, and an application thereof, belonging to the field of medicinal chemistry; specifically provided is the chemical compound represented by formula I, or its isomer, pharmaceutically acceptable salt, crystal, solvate, or prodrug, as well as their preparation methods and pharmaceutical compositions containing said chemical compound, and an application of said chemical compound or composition. The chemical compound has very good ability to inhibit mutant IDH2 enzyme activity and to inhibit mutant IDH2 neoplastic cells, and may be used for preventing and/or treating a tumor characterized by the presence of mutant IDH2.

Abstract: Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases.

Abstract: A quick wearing tool for a pair of magnetic eyelashes members, which includes a handle, a clip unit, an upper clip plate connected to a top end of the clip unit; and a lower clip plate moveable connected to the handle allowing upward and downward movement. The two clip plates have a magnetic polarity opposite to the magnetic eyelashes members, are made of iron materials or magnetic materials for forming a magnetic loop with the magnetic eyelashes members. The magnetic properties of the two clip plates are lower than that of the magnetic eyelashes members, therefore the magnetic eyelashes members are pre-loaded onto the two clip plates through magnetic attraction and then detached from the two clip plates to secure into position on real eyelashes by attraction between the two eyelashes members when the lower clip plate is moved upward towards the upper clip plate.

Abstract: Provided are a chemical compound of an isocitrate dehydrogenase inhibitor, and an application thereof, belonging to the field of medicinal chemistry; specifically provided is the chemical compound represented by formula I, or its isomer, pharmaceutically acceptable salt, crystal, solvate, or prodrug, as well as their preparation methods and pharmaceutical compositions containing said chemical compound, and an application of said chemical compound or composition. The chemical compound has very good ability to inhibit mutant IDH2 enzyme activity and to inhibit mutant IDH2 neoplastic cells, and may be used for preventing and/or treating a tumor characterized by the presence of mutant IDH2.

Abstract: A quick wearing tool for a pair of magnetic eyelashes members, which includes a handle, a clip unit, an upper clip plate connected to a top end of the clip unit; and a lower clip plate moveable connected to the handle allowing upward and downward movement. The two clip plates have a magnetic polarity opposite to the magnetic eyelashes members, are made of iron materials or magnetic materials for forming a magnetic loop with the magnetic eyelashes members. The magnetic properties of the two clip plates are lower than that of the magnetic eyelashes members, therefore the magnetic eyelashes members are pre-loaded onto the two clip plates through magnetic attraction and then detached from the two clip plates to secure into position on real eyelashes by attraction between the two eyelashes members when the lower clip plate is moved upward towards the upper clip plate.

Abstract: A novel nucleoside phosphoramidate compound of the formula below, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection, and having a good anti-HCV effect; a pharmaceutical composition having the compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof:

Abstract: The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.

Abstract: The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.

Abstract: In the field of pharmaceutical chemistry compounds of general formula I having heteroaryl alkynyl moiety or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof, and pharmaceutical compositions including these compounds, as well as uses of these compounds and compositions thereof in the manufacture of a medicament. The compounds have a strong inhibitory effect on BCR-ABL tyrosine kinase and are useful for treating diseases, such as tumors.